Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.

Published on Dec 1, 2013in Hepatology14.97
· DOI :10.1002/hep.26565
Kirsten Boonstra12
Estimated H-index: 12
Rinse K. Weersma50
Estimated H-index: 50
+ 15 AuthorsCyriel Y. Ponsioen42
Estimated H-index: 42
Extensive population-based studies are much needed to accurately establish epidemiology and disease course in patients with primary sclerosing cholangitis (PSC). We aimed to obtain population-based prevalence and incidence figures, insight in disease course with regard to survival, liver transplantation (LT), and occurrence of malignancies, as well as risk factors thereof. Four independent hospital databases were searched in 44 hospitals in a large geographically defined area of the Netherlands, comprising 50% of the population. In addition, all PSC patients in the three Dutch liver transplant centers and all inflammatory bowel disease (IBD) patients in the adherence area of a large district hospital were identified. All medical records were reviewed on-site, verifying diagnosis. Five hundred and ninety PSC patients were identified, resulting in an incidence of 0.5 and a point prevalence of 6.0 per 100,000. Median follow up was 92 months. Estimated median survival from diagnosis until LT or PSC-related death in the entire cohort was 21.3 years, as opposed to 13.2 years in the combined transplant centers cohort (n = 422; P < 0.0001). Colorectal carcinoma (CRC) risk was 10-fold increased, as compared to ulcerative colitis controls, and developed at a much younger age (39 years; range, 26-64), compared to IBD controls (59 years; range, 34-73; P = 0.019). Colonoscopic surveillance was associated with significantly better outcome. Conclusion: This study exemplifies that, for relatively rare diseases, it is paramount to collect observational data from large, population-based cohorts, because incidence and prevalence rates of PSC are markedly lower and survival much longer than previously reported. The selection of a bias-free, population-based cohort showed a significantly longer survival, compared to the tertiary referral cohort. CRC can develop at an early age, warranting surveillance from time of PSC diagnosis. (Hepatology 2013; 58:2045-2055).
  • References (41)
  • Citations (238)
#1Vikrant V. Sahasrabuddhe (NIH: National Institutes of Health)H-Index: 27
#2Munira Z. Gunja (UU: Utrecht University)H-Index: 2
Last.Katherine A. McGlynnH-Index: 35
view all 9 authors...
105 CitationsSource
#1Tine Jess (SSI: Statens Serum Institut)H-Index: 30
#2Jacob Simonsen (SSI: Statens Serum Institut)H-Index: 26
Last.Morten Frisch (SSI: Statens Serum Institut)H-Index: 59
view all 6 authors...
275 CitationsSource
#1Lisa J. Herrinton (KP: Kaiser Permanente)H-Index: 19
#2Liyan Liu (KP: Kaiser Permanente)H-Index: 28
Last.Fernando Velayos (UCSF: University of California, San Francisco)H-Index: 27
view all 6 authors...
151 CitationsSource
#1Marcel Janse (UMCG: University Medical Center Groningen)H-Index: 7
#2Laetitia E. Lamberts (UMCG: University Medical Center Groningen)H-Index: 12
Last.Rinse K. Weersma (UMCG: University Medical Center Groningen)H-Index: 50
view all 4 authors...
7 CitationsSource
#1Kirsten BoonstraH-Index: 12
#2Ulrich BeuersH-Index: 59
Last.Cyriel Y. PonsioenH-Index: 42
view all 3 authors...
273 CitationsSource
#1Airi JussilaH-Index: 9
#2Lauri J. Virta (Social Insurance Institution)H-Index: 23
Last.Martti Färkkilä (HYKS: Helsinki University Central Hospital)H-Index: 62
view all 6 authors...
41 CitationsSource
#1Enrique Chávez (CINVESTAV)H-Index: 7
#2Luis Castro-Sánchez (CINVESTAV)H-Index: 11
Last.Pablo Muriel (CINVESTAV)H-Index: 34
view all 7 authors...
15 CitationsSource
#1Jh Ngu (Canterbury of New Zealand)H-Index: 8
#2Richard B. Gearry (Canterbury of New Zealand)H-Index: 51
Last.Catherine Am Stedman (Canterbury of New Zealand)H-Index: 32
view all 4 authors...
65 CitationsSource
#1Laetitia E. Lamberts (UMCG: University Medical Center Groningen)H-Index: 12
#2Marcel Janse (UMCG: University Medical Center Groningen)H-Index: 7
Last.Rinse K. WeersmaH-Index: 50
view all 5 authors...
23 CitationsSource
#1Joana Torres (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 16
#2G Pineton de Chambrun (UCSD: University of California, San Diego)H-Index: 7
Last.Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 129
view all 5 authors...
76 CitationsSource
Cited By238
#1Peter L. Labib (UCL: University College London)H-Index: 1
#2George Goodchild (UCL: University College London)H-Index: 2
Last.Stephen P. Pereira (UCL: University College London)H-Index: 43
view all 3 authors...
3 CitationsSource
#1Jerzy Ostrowski (Curie Institute)H-Index: 23
#2Krzysztof Goryca (Curie Institute)H-Index: 11
Last.Michal Mikula (Curie Institute)H-Index: 1
view all 15 authors...
1 CitationsSource
#1Jorn C Goet (Erasmus University Medical Center)H-Index: 3
#2Annarosa Floreani (UNIPD: University of Padua)H-Index: 43
Last.Bettina E. Hansen (U of T: University of Toronto)H-Index: 6
view all 10 authors...
1 CitationsSource
#1Christopher L. Bowlus (UC Davis: University of California, Davis)H-Index: 41
#2Joseph K. Lim (Yale University)H-Index: 34
Last.Keith D. Lindor (ASU: Arizona State University)H-Index: 96
view all 3 authors...
#1Ayesha Shah (UQ: University of Queensland)H-Index: 4
#2Darrel Crawford (UQ: University of Queensland)
Last.Gerald Holtmann (UQ: University of Queensland)H-Index: 53
view all 14 authors...
#1Mike van der Have (UU: Utrecht University)H-Index: 10
#2Bas Oldenburg (UU: Utrecht University)H-Index: 41
#1Ming-Hsi Wang (Mayo Clinic)H-Index: 1
#2Omar Y. Mousa (Mayo Clinic)H-Index: 3
Last.William Alvis Faubion (Mayo Clinic)H-Index: 38
view all 12 authors...
1 CitationsSource
#1P. J. PatelH-Index: 1
#2Declan Connoley (Monash University)
Last.William RosenbergH-Index: 51
view all 5 authors...
#1Marit Mæhle Grimsrud (University of Oslo)H-Index: 1
#2Trine Folseraas (University of Oslo)H-Index: 6
View next paperEpidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review